<DOC>
	<DOCNO>NCT00565981</DOCNO>
	<brief_summary>Open label multicenter , two-step , non-randomized ( pilot ) study analyze safety 4 cycle 3-day 40mg/m2 oral fludarabine simultaneous thrice weekly application 30mg alemtuzumab s.c. patient B-CLL disease 1st 2nd relapse primary treatment disease refractory therapy 1st 2nd line ( include Fludarabine , ) . This regimen precede escalation phase 3-10-30 mg alemtuzumab s.c. After first phase ( complete treatment 7 patient ) interim analysis safety efficacy perform . In case sufficient risk benefit assessment follow enrollment 21 patient . Final analysis safety preliminary efficacy base patient enrol .</brief_summary>
	<brief_title>A Pilot Trial With Subcutaneous Alemtuzumab Oral Fludarabinephosphate Determination Safety , Efficacy Molecular Profiling Prediction Response</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<criteria>Male female patient CD23+ , CD5+ , CD19+ , light chain monoclonal B CLL 1st 2nd relapse fludarabine primary treatment regimen refractory primary secondary treatment ( include fludarabine ) simultaneously indication treatment accord NCI Workshop Criteria 1996 Age 1975 WHO performance score 02 Informed consent give patient HIV positive positive Hepatitis B C active uncontrolled infection child bear age without adequate control fertility , pregnant lactate woman intolerance towards ingredient either oral fludarabine alemtuzumab allergy foreign proteins previous treatment alemtuzumab treatment experimental drug within previous 2 month second malignant disease ( non CLL ) CLL transformation ( Richter syndrome ) decrease kidneyfunction creatinineclearance &lt; 30ml/min severe concomitant disease major organ dysfunction patient unable comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>B-CLL</keyword>
	<keyword>refractory</keyword>
	<keyword>molecular profiling</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>fludarabinephosphate</keyword>
</DOC>